News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>CMSI: 3SBIO (01530.HK) Expected to Benefit from Maturation in Immunology Assets; TP Raised to $25
3SBIO (01530.HK) signed the largest single asset transaction in China's biopharmaceutical industry with Pfizer, involving an upfront payment of US$1.25 billion and a total scal...
Reset
Send
The window will close in 5 seconds
<Research>CMSI: 3SBIO (01530.HK) Expected to Benefit from Maturation in Immunology Assets; TP Raised to $25
Close
Recommend
3
Positive
6
Negative
3
 
SHORT SELL
 
STOCK INFO

3SBIO (01530.HK)  -0.020 (-0.100%)    Short selling $111.25M; Ratio 5.858%   signed the largest single asset transaction in China's biopharmaceutical industry with Pfizer, involving an upfront payment of US$1.25 billion and a total scale of US$6 billion, according to CMSI's research report.

CMSI had previously alerted investors about the licensing transfers of PD-1xVEGF and TL1A, and expected further maturation in immunology assets to potentially drive another valuation upgrade, based on the company's rich product line, aiming to launch approx. 10 products, submit new drug applications from 2025 to 2027 and continuously expanded indications, as well as internal new product lines, validated business expansion efforts and enriched hair loss, dermatology and autoimmune product portfolios, according to the report.

Related NewsCICC Raises 3SBIO (01530.HK) TP by 56.3%, Keeps Rating at Outperform
Therefore, the broker kept rating at Buy on 3SBIO, and raised its target price to $25.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-05-22 16:25.)

AASTOCKS Financial News
Website: www.aastocks.com
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.